Application of group of metabolic markers in early diagnosis of metabolic syndrome

Abstract

The invention discloses an application of a group of metabolic markers in early diagnosis of a metabolic syndrome. The metabolic markers at least comprise glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0), and further comprise tyrosine or phenylalanine. In a validation set of a specific embodiment, the accuracy degree for distinguishing a health volunteer and a metabolic syndrome patient through joint use of tyrosine, phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0) and glutamine-leucine reaches 80.5%, and the accuracy degree for distinguishing the health volunteer andthe metabolic syndrome patient through joint use of phenylalanine, glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0)reaches 82.6%. Therefore, the abovementioned metabolic markers have high accuracy degree for diagnosis of the metabolic syndrome, can be prepared into a metabolic syndrome diagnosis kit and are used for early diagnosis of a healthy person suffering from the metabolic syndrome.

Description

technical field

[0001] The invention belongs to the field of disease detection and diagnosis, and relates to the discovery and application of disease diagnostic markers, in particular to the application of metabolic markers in the early diagnosis of metabolic syndrome and colorectal cancer. Background technique

[0002] Colorectal cancer is one of the common malignant tumors and has become one of the three major cancers in China, with a prevalence rate as high as 46.8 / 100,000, and 130,000 to 160,000 new cases each year. If colorectal cancer is detected early, the 5-year survival rate of patients can reach more than 90%; if it is not detected early enough that it has metastasized to other organs or tissues, the survival rate is only about 10%. Therefore, early diagnosis of colorectal cancer is very important to improve the survival rate of colorectal cancer patients.

[0003] Patients with metabolic syndrome have a significantly higher probability of developing colorectal ca...

Examples

Embodiment 1

[0041] Example 1: Diagnostic Efficiency of Target Metabolites in Differentiating Healthy Subjects, Patients with Metabolic Syndrome or Patients with Colorectal Cancer

[0042] 1. Experimental samples

[0043] Training set samples: Collect 120 healthy subjects, 120 patients with metabolic syndrome and 120 patients with colorectal cancer who were age- and gender-matched in Xiaoshan area and Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine according to strict screening and exclusion criteria.

[0044] Validation set samples: 580 healthy subjects, 577 patients with metabolic syndrome, and 437 patients with colorectal cancer were collected from Xiaoshan area, Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, and Taizhou Cancer Hospital according to strict screening and exclusion criteria.

[0045] The inclusion criteria for healthy subjects, patients with metabolic syndrome and patients with colorectal cancer are as follows:

[0...

Embodiment 2

[0127] Example 2: Diagnosis of a diagnostic kit for distinguishing healthy subjects, patients with metabolic syndrome or patients with colorectal cancer

[0128] 1. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which contains standard products of diagnostic markers, and the diagnostic markers are isoleucine, tyrosine, benzene Alanine, tryptophan, glutamine-leucine, p-hydroxycinnamic acid or phosphatidylethanolamine PE (18:2(9Z,12Z) / P-18:0).

[0129] 2. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which contains standards for diagnostic markers, including tyrosine and glutamine-leucine acid.

[0130] 3. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which con...

technical field

[0001] The invention belongs to the field of disease detection and diagnosis, and relates to the discovery and application of disease diagnostic markers, in particular to the application of metabolic markers in the early diagnosis of metabolic syndrome and colorectal cancer. Background technique

[0002] Colorectal cancer is one of the common malignant tumors and has become one of the three major cancers in China, with a prevalence rate as high as 46.8 / 100,000, and 130,000 to 160,000 new cases each year. If colorectal cancer is detected early, the 5-year survival rate of patients can reach more than 90%; if it is not detected early enough that it has metastasized to other organs or tissues, the survival rate is only about 10%. Therefore, early diagnosis of colorectal cancer is very important to improve the survival rate of colorectal cancer patients.

[0003] Patients with metabolic syndrome have a significantly higher probability of developing colorectal ca...

Examples

Embodiment 1

[0041] Example 1: Diagnostic Efficiency of Target Metabolites in Differentiating Healthy Subjects, Patients with Metabolic Syndrome or Patients with Colorectal Cancer

[0042] 1. Experimental samples

[0043] Training set samples: Collect 120 healthy subjects, 120 patients with metabolic syndrome and 120 patients with colorectal cancer who were age- and gender-matched in Xiaoshan area and Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine according to strict screening and exclusion criteria.

[0044] Validation set samples: 580 healthy subjects, 577 patients with metabolic syndrome, and 437 patients with colorectal cancer were collected from Xiaoshan area, Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, and Taizhou Cancer Hospital according to strict screening and exclusion criteria.

[0045] The inclusion criteria for healthy subjects, patients with metabolic syndrome and patients with colorectal cancer are as follows:

[0...

Embodiment 2

[0127] Example 2: Diagnosis of a diagnostic kit for distinguishing healthy subjects, patients with metabolic syndrome or patients with colorectal cancer

[0128] 1. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which contains standard products of diagnostic markers, and the diagnostic markers are isoleucine, tyrosine, benzene Alanine, tryptophan, glutamine-leucine, p-hydroxycinnamic acid or phosphatidylethanolamine PE (18:2(9Z,12Z) / P-18:0).

[0129] 2. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which contains standards for diagnostic markers, including tyrosine and glutamine-leucine acid.

[0130] 3. A diagnostic kit for colorectal cancer, which is used for the early diagnosis of colorectal cancer in healthy people or patients with metabolic syndrome, which con...

Images